The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies
  • The company will also use the funds to progress its cell therapies to first-in-human clinical studies
  • Under the SPP, shareholders will be able to subscribe for $30,000 worth of new shares at 17.5 cents per share
  • Prescient CEO and Managing Director Steven Yatomi-Clarke says the company is seeking to maintain its momentum of “incredible” growth and its position at the forefront of oncology innovation
  • Shares in Prescient Therapeutics are down 14.3 per cent and trading at 18 cents at 2:51 pm AEST

Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies.

The company said it would also use the funds to progress its cell therapies to first-in-human clinical studies and for general working capital.

Under the SPP, shareholders will be able to subscribe for $30,000 worth of new shares at 17.5 cents per share. This price represents a 14.6 per cent discount to Prescient’s volume-weighted average price over the five trading days before August 24.

Prescient CEO and Managing Director Steven Yatomi-Clarke said the company was seeking to maintain its momentum of “incredible” growth and its position at the forefront of oncology innovation.

“Prescient continues to build out a diverse and innovative pipeline of personalised therapies for cancer,” Mr Yatomi-Clarke said.

The SPP is anticipated to close on September 29, with results to be announced on October 3 and shares issued on October 5.

Last week, Prescient signed a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform.

Under the agreement, a development will be constructed to evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on the OmniCAR platform using non-viral methods.

Shares in Prescient Therapeutics were down 14.3 per cent and trading at 18 cents at 2:51 pm AEST.

ptx by the numbers
More From The Market Online

Market Close: ASX slides 1.58% as global AI sell-off rattles investors

My nerves, along with my portfolio, have taken a beating over the last couple of weeks – and I’m sick of seeing red!

Market Close: Materials drag ASX lower as seven sectors finish higher

The Australian share market finished lower on Monday, with weakness across the resources sector weighing on the broader market despite gains across most

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.